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Abstract
Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7
receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as
targeted agents for these leukemias.
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The importance of interleukin-7 receptor signaling
for B and T cell development in normal and
malignant conditions
Cytokine signaling, orchestrated by various ligands and
more than 30 different receptors, plays a critical role dur-
ing hematopoiesis. Cytokines that bind to receptors con-
taining the common gamma chain (IL2RG) such as IL2,
IL4, IL7, IL9, IL15, and IL21 are important for B and T cell
development and function [1]. The IL7 receptor has re-
ceived much of attention because it is a marker for early
lymphoid progenitor cells, it is essential for both B and T
cell development, and it was recently identified as a domin-
ant oncogene in acute lymphoblastic leukemia (ALL). We
will focus here on the IL7 receptor complex as an example
of how cytokine receptor signaling can be hijacked by
leukemia cells.
The IL7 receptor is a heterodimeric receptor consisting
of the IL7 receptor alpha chain (IL7R) and the common
gamma chain (IL2RG). These receptor units associate with
Janus kinase 1 (JAK1) and JAK3, respectively, and these
kinases are both activated upon binding of IL7 to the re-
ceptor (Fig. 1). Loss-of-function mutations in IL2RG,
IL7R, or JAK3 lead to impaired B and T cell development
and have been identified in patients with severe combined
immunodeficiency disease, clearly illustrating that this sig-
naling axis is essential for normal lymphocyte develop-
ment [1]. In contrast, gain-of-function mutations in IL7R,
JAK1, or JAK3 lead to ligand-independent activation of
IL7 receptor signaling, and have been identified in ALL
and in various lymphoma types.
Activating mutations in IL7R are frequently found in T
cell ALL (T-ALL) and B cell ALL (B-ALL) [2, 3]. These
IL7R activating mutations are located in exon 6 and mostly
lead to the incorporation of an unpaired cysteine close to
the transmembrane domain of the receptor (Fig. 1). In this
way, the mutant IL7R protein can form homodimers by
the formation of disulfide bonds resulting in cytokine-
independent activation of the downstream signaling path-
ways. In a minority of ALL cases, the IL7R mutations do
not involve the insertion of a cysteine amino acid, and
those insertions occur within the transmembrane domain,
most likely resulting in ligand-independent activation of
heterodimeric receptors.
In addition to mutations in the receptor itself, also mu-
tations in the tyrosine kinase JAK3 are frequent in T-ALL
[2, 4, 5], while JAK1 activating mutations occur at a low
frequency in T or B ALL (Fig. 1) [2, 6]. Due to the re-
stricted expression pattern of IL7R, IL7R mutations are
limited to lymphoid malignancies, while JAK1 and JAK3
mutations could also be expected in myeloid leukemias
and even in any type of cancer. Indeed, JAK1 mutations
have also been detected in a variety of epithelial tumors,
with the highest frequency in hepatocellular carcinoma
(http://cancer.sanger.ac.uk).
Targeted treatment strategies
Over the last decades, combination chemotherapy has
been optimized for the treatment of ALL, and childhood
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ALL can now be cured in more than 80 % of children.
Patients, however, suffer from serious short-term and
long-term side effects of intensive treatment, and adult
ALL patients have a poor outcome. With an increasing
understanding of the molecular defects implicated in
the pathogenesis of ALL, it is now possible to design
patient-specific therapies where treatment is based on
the mutational status of the leukemia cells. Since the
IL7 receptor complex (JAK1, JAK3, IL7R) is mutated
in up to 25 % of the T-ALL cases, this could be one of
the new therapeutic targets to be explored.
Protein tyrosine kinases are interesting proteins from a
therapeutic perspective, because these enzymes are easy
to target with small molecule inhibitors and these pro-
teins are often mutated and constitutively activated in
cancer. The ABL inhibitor imatinib has revolutionized
treatment of chronic myeloid leukemia, and also in
BCR-ABL positive ALL, the combination of ABL kinase
inhibitors with chemotherapy has shown promising re-
sults. Since the initial successes with imatinib, many
other kinase inhibitors have been developed, including a
variety of JAK kinase inhibitors (Table 1). While most of
these inhibitors are still under development, the JAK1/
JAK2-selective inhibitor ruxolitinib is already FDA ap-
proved for treatment of patients with myelofibrosis, and
the JAK3-selective inhibitor tofacitinib received FDA ap-
proval for the treatment of patients with rheumatoid
arthritis. These data demonstrate that JAK kinase inhibi-
tors can be administered safely and open new possibil-
ities for the treatment of T-ALL with IL7R, JAK1, or
JAK3 mutations. With T-ALL being a rare leukemia, it is
very fortunate that numerous JAK inhibitors are already
available and could potentially be repurposed for the
treatment of T-ALL.
It has been reported that JAK1 [7], IL7R [3], and JAK3
[8] mutants are sensitive to JAK-selective inhibition. JAK1
Fig. 1 Schematic representation of the interleukin-7 (IL7) receptor signaling complex. Arrows indicate locations that are often found to be mutated.
Activation of the receptor complex by ligand binding or by mutation in IL7R, JAK1, or JAK3 causes phosphorylation of STAT proteins, which leads to
activation of survival and proliferation pathways
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is indispensable for IL7R mutants in order to maintain ac-
tivation of downstream proteins such as STAT5 [3]. Simi-
larly, we reported several lines of evidence that JAK1 is
required for the transforming mechanisms of most JAK3
mutants. Thus, although the number of ALL patients with
specific mutations in IL7R, JAK1, or JAK3 is low, all these
cases together represent about 27 % of T-ALL cases and
are all likely to respond to JAK inhibitors [9].
In vivo models for testing potential compounds
We recently showed that most JAK3 mutations, identi-
fied in T-ALL patient samples, caused leukemia in a
mouse model [8]. In the development of mouse models
expressing JAK3 mutations, we mainly focused on the
JAK3 M511I mutation, which is the most common mu-
tation found in T-ALL. Mice receiving bone marrow
transplantation with cells expressing the JAK3 M511I
mutant developed a lymphoproliferative disease over the
first 12 weeks, followed by progression to an acute phase
characterized by a rapid increase in white blood cell
(WBC) counts. All animals eventually succumbed to the
disease within 14 to 28 weeks after receiving the bone
marrow transplantation [8]. The disease was characterized
by splenomegaly, enlarged thymus, and enlarged lymph
nodes. All mice showed an accumulation of CD8 single
positive immature T cells in the peripheral blood and
hematopoietic tissues. The leukemic cells were transplant-
able to secondary recipient mice and were characterized
by the presence of additional mutations in Notch1, Pten,
Kras, and other genes. Mice which received a bone mar-
row transplant of cells expressing wild-type JAK3 did not
develop any disease phenotype [8].
Primary and secondary transplanted mice were subse-
quently used to test the efficacy of the JAK3-selective
Table 1 JAK1 and JAK3-selective inhibitors currently in clinical studies
Name Selectivity Patient group Clinical phase
Baricitinib (LY3009104) JAK1/2 Rheumatoid arthritis Phase 3
Psoriasis
Ruxolitinib (INCB18424) JAK1/2 Acute leukemia Phase 1/2
Chronic myeloid leukemia (CML)
Acute myeloid leukemia (AML) FDA approved
Myelofibrosis
Decernotinib (VX-509) JAK3 Rheumatoid arthritis Phase 2/3
Tofacitinib
(CP-690550)
JAK3 Rheumatoid arthritis FDA approved
INCB039110 JAK1 Primary myelofibrosis Phase 2
Post-polycythemia vera fibrosis
Post-essential thrombocythemia myelofibrosis
PF-04965842 JAK1 Plaque psoriasis Phase 2
Filgotinib (GLPG0634) JAK1 Rheumatoid arthritis Phase 2
Crohn’s disease
INCB047986 JAK1 Rheumatoid arthritis Phase 2
Momelotinib (CYT387) JAK1/JAK2 Primary myelofibrosis Phase 1/2
Post-polycythemia vera myelofibrosis Phase 2
Post-essential thrombocythemia myelofibrosis
Polycythemia vera
Essential thrombocythemia Phase 2
GSK2586184 JAK1 Psoriasis Phase 2
Systemic lupus erythematosus
AT9283 JAK2/JAK3 Multiple myeloma Phase 2
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inhibitor, tofacitinib (Xeljanz, Pfizer), to treat leukemia
progression. Mice treated with tofacitinib showed a de-
crease in WBC count, while mice receiving placebo
treatment had an increase in WBC count during treat-
ment. Pathological analysis of tissues showed a high
percentage of apoptotic cells in tofacitinib-treated mice,
while placebo-treated mice had very low amount of
apoptotic cells. Spleen and thymus weight was signifi-
cantly lower in tofacitinib-treated mice compared to
placebo-treated mice. These data demonstrate that JAK
inhibitors such as tofacitinib show activity in mouse
leukemia models [8]. However, when treatment was
stopped, WBC counts increased, and all animals even-
tually succumbed to the disease, showing that kinase
inhibitors alone cannot lead to complete eradication of
the leukemia cells in this mouse model.
In a separate study, Maude and colleagues investigated
the efficacy of ruxolitinib for the treatment of early T
cell precursor ALL (ETP-ALL) using xenografted human
leukemia samples. Injection of ETP-ALL samples in im-
mune deficient NSG mice led to the expansion of the
leukemia cells in vivo, which was observed by increasing
numbers of human blast cells in the peripheral blood
and spleen of the NSG mice over time. Treatment of
these animals with ruxolitinib, a JAK1/JAK2 inhibitor,
caused a dramatic reduction of peripheral and spleen
blasts, even as a single agent. Interestingly, the efficacy
of ruxolitinib was observed not only in three samples
with JAK1 or JAK3 mutation, but also in two ETP-ALL
samples without JAK1, JAK3, or IL7R mutation [10].
These data indicate that JAK inhibitors are promising
agents for the treatment of T-ALL, and that clinical tri-
als to test these agents are warranted. JAK1, JAK3, or
IL7R mutations predict response to JAK inhibitors, but
even T-ALL cases without such mutations could poten-
tially respond to JAK inhibition, most likely due to the
presence of other, yet unknown, mechanisms leading to
activation of the JAK/STAT pathway.
What about resistance?
Targeted agents such as tyrosine kinase inhibitors are very
active and specific and typically show strong anti-cancer
effects, but suffer from the fact that they bind to the target
kinase in one specific part, typically the ATP-binding
pocket. As a consequence, oncogenic kinases can become
resistant to the inhibitor by mutating a single amino acid,
a problem that has been observed in nearly all clinical ap-
plications of targeted cancer treatment.
It is too early to tell whether JAK inhibitors would
show clinical efficacy for the treatment of T-ALL, but in
case this is successful, can we also expect resistance and
how could we design the best inhibitors? Would it be
possible to design a strategy to prevent or limit the de-
velopment of resistance? The intimate interplay between
the JAK1 and JAK3 kinase at the IL7 receptor may offer
opportunities for the prevention of resistance development.
A recent study showed that cells transformed by a JAK3
mutant could become resistant to a JAK3-selective inhibitor
by acquiring another activating mutation in JAK1 [11]. By
targeting both JAK1 and JAK3 in JAK3 mutant leukemia
cells, it may be very difficult for the leukemia cells to over-
come this block by just one mutation. Moreover, our study
showed that combination of JAK3-selective and JAK1-
selective inhibitors had a clear synergistic effect on the
growth of JAK3 mutant cells [8]. In this way, the dose of
both drugs could be lowered while still achieving a good in-
hibition of the signaling pathways.
While combined inhibition of both JAK1 and JAK3
could be beneficial for the treatment of a subset of the T-
ALL cases, it is also clear that another group of mutants
are very much dependent on JAK1 or JAK3 only. It will be
important to further clarify the mechanisms by which the
different JAK1, JAK3, and IL7R mutants transform cells.
Better insight in the exact signaling pathways that are acti-
vated by each of the mutants could help the rational selec-
tion of targeted agents to achieve better responses and
prevent the development of resistance.
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